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the lowest diagnostic detection accuracy (74%), followed by MRI (80%) and EUS 
(94%). With CT as the baseline comparator, the ICERs for MRI ($2,783) and EUS 
($2,200) demonstrated that both were acceptable alternatives. CONCLUSIONS: 
Patients or physicians with low risk-tolerance are advised to avoid the watchful 
waiting approach. EUS, MRI and CT are all cost-effective diagnostic choices. 
Among the four choices, EUS is associated with the lowest risk and highest costs. 
EUS is the best monitoring choice when risk must be minimized irrespective of 
cost. Alternatively, annual MRI and CT scans may serve as a preferred option for 
patients and physicians aiming to balance risk-tolerance with procedure cost.  
 
PGI19  
COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION COMPARED TO 
ENDOSCOPIC SURVEILLANCE FOR PATIENTS WITH BARRETT'S ESOPHAGUS 
WITH LOW GRADE DYSPLASIA  
Church J1, Goodall S1, Gurgacz S2, Whiteman DC3, Lord RV4 
1University of Technology Sydney, Sydney, Australia, 2Royal Australian College of Surgeons, 
Adelaide, Australia, 3Queensland Institute of Medical Research, Brisbane, Australia, 4University 
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OBJECTIVES: Current guidelines for the management of patients with Barrett’s 
esophagus (BE) with high grade dysplasia recommend radiofrequency ablation 
(RFA) as a treatment, based upon demonstrated clinical and cost-effectiveness. 
For patients with BE with low grade dysplasia (LGD), in contrast, the mainstay of 
management is surveillance endoscopy. The aims of this study were to estimate 
whether RFA is cost-effective for patients with Barrett’s LGD compared to 
surveillance and to determine which factors influence the cost-effectiveness. 
METHODS: A cost-utility analysis was undertaken. A state transition Markov 
model was developed to estimate the costs and benefits of using RFA compared 
to surveillance in LGD. All direct medical costs were estimated from the 
perspective of the Australian health care system with adjustments for the US 
health care system. The model was run for the lifetime of the cohort of patients 
where quality of life differed by disease state. The incremental cost per quality 
adjusted life year (QALY) was estimated and uncertainty was explored using 
sensitivity analyses. RESULTS: Clinical evidence suggests that RFA is superior in 
treating LGD compared to surveillance. Replacing surveillance with RFA would 
yield an additional benefit of 0.129 QALYs. However the cost-effectiveness of RFA 
is highly uncertain. The main drivers of the cost-effectiveness results are the 
effectiveness of RFA, the probability of progression to cancer, and the cost of 
RFA. CONCLUSIONS: The available data suggest that active treatment with RFA 
provides significantly better clinical outcomes than surveillance, but the cost-
effectiveness of RFA in this patient group remains highly uncertain. RFA is not 
cost-effective if the low estimates of cancer risk for LGD from recent population-
based studies are used, but the accuracy of these estimates is unclear. Accurate 
estimates of the risk of developing cancer in patients with no dysplasia or LGD 
are needed to conduct valid and reliable cost-effectiveness analyses.  
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ASSESSMENT OF PRACTICE PATTERNS AND TREATMENT-FAILURE MEDICAL 
COSTS AMONG PATIENTS WITH CHRONIC CONSTIPATION: FINDINGS FROM A 
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Menzin J1, Huang H1, Carson RT2, Taylor DCA3, Sarocco P3, Blum SI2 
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OBJECTIVES: Chronic constipation (CC) is a common chronic functional 
gastrointestinal disorder that may be associated with increased utilization of 
health care resources. The objective of this study was to understand resource 
utilization and associated costs for patients with CC based on treatment 
response. METHODS: A web-based survey was conducted with a sample of 
primary care physicians (PCPs) and gastroenterologists (GEs) across different US 
regions. The survey captured data on referral patterns (to/from GEs), 
test/procedure ordering, and follow-up physician visits for typical patients who 
did and did not achieve satisfactory relief of symptoms to a recent treatment for 
CC (“response”). Survey items included questions regarding the proportion of 
patients who would receive tests/procedures and follow-up physician visits. 
Health care costs were estimated by applying associated unit costs (derived from 
the 2012 Medicare physician payment schedule) to the corresponding utilization. 
All patients were assumed to begin treatment with PCPs. Median and mean costs 
of treatment failure were calculated as the corresponding cost differences 
between physician-deemed non-responders and responders, incorporating both 
PCP work-up costs and the costs of referrals to GEs. RESULTS: Twenty PCPs and 
21 GEs completed the survey. These physicians treated a mean of 58 adults per 
month for CC. Most non-responders were referred to GEs by PCPs (median: 78%; 
mean: 68%). Non-responders were more likely to receive a test/procedure 
compared with responders (median: 90 vs. 0% for both PCPs and GEs; mean: 72 
vs. 5% for PCPs; 72 vs. 24% for GEs). Thyroid function tests and colonoscopy were 
the most common tests/procedures that would be ordered. Median (mean) 
expected cost of follow-up due to non-response was estimated to be $1,132 
($865). CONCLUSIONS: Patients with CC who do not respond satisfactorily to 
treatments are likely to require additional follow-up testing and referrals to 
specialists, potentially leading to increased health care costs.  
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OBJECTIVES: Opioid-induced constipation (OIC) is a common gastrointestinal 
side effect of opioid treatment that can lead to alteration or discontinuation of 
opioid therapy. This multinational cross-sectional survey assessed OIC burden of 
illness. METHODS: Health care providers (HCPs) and a sample of their patients 
prescribed opioids for chronic noncancer pain were surveyed regarding patient 
laxative use, OIC symptoms, treatment patterns, and OIC impact on patient’s 
pain management/daily life. RESULTS: HCPs (n=63) and patients from Canada 
(n=64), France (n=60), Germany (n=60), the UK (n=60), and the United States 
(n=60) participated. Sixty-nine percent of patients were characterized as 
inadequate responders to laxative treatment (used laxatives on ≥4 days in past 
two weeks and had continued constipation symptoms or symptom resolution 
with laxative side effects). Inadequate responders were more likely to have 
started an opioid regimen in the last six months and to have ≤1 bowel movement 
(BM)/wk versus ≥2 compared with responders. The proportion of patients self-
reporting the following common gastrointestinal symptoms were higher than 
what physicians reported as the percent of their patients complaining of these 
symptoms: few normal or spontaneous BMs (88% vs 65%), hard lumpy stools 
(87% vs 71%), BMs different than normal (82% vs 59%), bloating (78% vs 71%), and 
abdominal discomfort/stomach cramps (75% vs 62%). Patients reported taking 
opioids less often (53%) or lowering the dose (57%) as a strategy to alleviate 
constipation, whereas HCPs reported recommending these strategies to 
approximately 10% of their patients with OIC. Approximately 40% of patients 
reported that constipation made it quite a bit harder or extremely harder to live 
with their chronic pain. CONCLUSIONS: Results indicate a disconnect in the 
frequency that OIC symptoms are experienced by patients versus perceived by 
their treating HCPs and also in the frequency of opioid dosing alteration to 
alleviate OIC by patients versus recommended by their HCPs.  
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A 10-YEAR LITERATURE REVIEW  
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OBJECTIVES: Constipation is the most common and often most debilitating  
side effect of opioid therapy for chronic pain. It has been reported that some 
patients rank constipation as a more common source of distress than their pain. 
Opioid-induced constipation (OIC) compounds the burden in these patients  
and may lead to opioid alterations in dosing regimen, discontinuation, 
inadequate pain management, and increased cost of care. METHODS: Using 
standard methodology, a targeted literature review was undertaken of studies 
published in the last 10 years (2002–2012) reporting quality of life (QOL) in 
patients with OIC receiving opioid therapy for cancer or noncancer pain. The 
review focused on PubMed (MEDLINE) and Embase; abstracts from recent key 
conferences/meetings for gastroenterology and pain were also reviewed. 
RESULTS: A limited number of publications (one review, four surveys, two small 
qualitative studies) were identified. While only the PAC-QOL has been validated 
in this population, various additional instruments were used to describe OIC 
impact on QOL, such as EQ-5D, the SF-8 questionnaire, a 5-point scale, an 11-
point scale, and qualitative descriptions. The burden of OIC on patient QOL was 
found to be considerable, with OIC patients experiencing worse QOL than 
patients without OIC in all four surveys. Of note, one survey showed that 
increasing severity of constipation correlated with decreasing QOL, while 
another indicated that patients with severe constipation were less satisfied with 
their pain treatment versus patients with mild, moderate, or no constipation. 
Mean satisfaction with pain treatment with no, mild, moderate and severe 
constipation was 6.6, 6.6, 6.2 and 5.2 (10-very satisfied). CONCLUSIONS: Current 
literature on the impact of OIC on QOL is very limited but consistently suggests 
that OIC adversely impacts QOL. More research is needed to fully quantify the 
impact on QOL and standardize research methodology. Alleviation of OIC may 
improve QOL and optimize pain management among these patients.  
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DEPRESSION FOLLOWING THE COLECTOMY SURGERY  
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OBJECTIVES: To investigate the factors that potentially influence the UC 
patients’ anxiety and depression after having a colectomy utilizing patient 
survey tools. METHODS: A cross-sectional survey was administered online or via 
paper to patients ≥18 years of age with UC who had a colectomy surgery within 
the last 10 years in Canada, Australia, and the UK. Anxiety and depression was 
measured using the Hospital Anxiety and Depression Scale (HADS); scores > 8 on 
the respective anxiety and depression scales indicate the presence of the 
condition. Other scales used included the Inflammatory Bowel Disease 
Questionnaire (IBDQ), 5-item EuroQol (EQ-5D) questionnaire, Body Image 
Questionnaire (BIQ), Medical Outcomes Study Sexual Functioning Scale (MOS-
SFS), dietary restriction questions, and World Health Organization Health and 
Work Performance Questionnaire-Absenteeism and Presenteeism Questions 
(WHO-HPQ-AP). Logistic regression was used to investigate factors associated 
with anxiety. RESULTS: A total of 424 patients participated from Canada, UK, and 
Australia. Gender was equally distributed with a mean age of 42±13 years. 
Respondents were diagnosed with UC with a mean of 11.8±8.5 years ago and first 
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surgery occurred a mean of 4.2±2.5 years ago. Based on the HADS, 31% and 16% 
of patients had clinically meaningful anxiety and depression, respectively. 
Depression was significantly associated with poorer totaI IBDQ scores (p<0.0001) 
and higher BIQ scores (p<0.0001). Females are 2.15 times more likely to have 
anxiety than males (OR 2.15, 95% CI 1.19-3.88). Other factors associated with 
anxiety include loss of work productivity (OR 1.39, 95% CI 1.18-1.64) and poorer 
body image (OR 1.12, 95% CI 1.04-1.20). CONCLUSIONS: The findings from this 
multi-national study provide insight on important factors to inform patient-
physician communications both prior to and post-colectomy.  
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OBJECTIVES: Fatigue is the most common side-effect of treatment for chronic 
hepatitis C virus (CHC) infection with peginterferon-α and ribavirin (PR). 
Adequacy of the Fatigue Severity Scale (FSS) total scores for evaluating fatigue 
from the patients’ perspective in CHC trials was assessed using blinded data 
from two CHC clinical trials. METHODS: 386 treatment-naïve patients (PILLAR) 
and 462 treatment-experienced patients (ASPIRE) were randomized to receive 
simeprevir (TMC435), a potent, oral, once-daily, investigational HCV NS3/4A 
protease inhibitor in Phase III clinical development and PR or placebo/PR. 
Patients completed the FSS and EQ5D in their native language throughout the 72 
week trials. Reliability of the FSS was evaluated using Cronbach’s co-efficient a 
at Week 24 (internal consistency reliability) and intraclass correlation (ICC) 
between FSS at Weeks 12 and 24 in stable patients (<0.5 g/dL change in 
hemoglobin between Weeks 12/24). Concurrent validity was assessed as 
correlation with the EQ5D visual analog scale (VAS). Known-groups validity of 
FSS scores was assessed using mean comparison by levels on the EQ5D daily 
activity item and by clinician-rated fatigue AEs at Week 24. Distribution- and 
anchor-based methods identified values representing a meaningful change in 
individual and mean FSS scores. RESULTS: FSS scores were highly reliable 
(Cronbach’s α = 0.95, 0.96 and ICC: 0.74, 0.86 for PILLAR and ASPIRE, respectively). 
Concurrent validity (correlation of FSS and EQ5D VAS=-0.63, -0.66) and known 
groups validity (mean FSS scores by EQ5D daily activity levels or fatigue AEs 
severity (p < 0.05) were confirmed. Analyses suggest that a meaningful change in 
mean FSS scores ranges from 0.33-0.82, and that a 1 point change is a 
conservative indicator of an important within-subject change in FSS score. 
CONCLUSIONS: The Fatigue Severity Scale provides reliable and valid 
assessment and quantification of fatigue for clinical trials in patients with CHC 
infection.  
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DEVELOPMENT OF PATIENT-REPORTED OUTCOMES (PRO) AND OBSERVER-
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Yen L1, Flood E2, Beusterien K3, Tucker J2, Stout B2, Ahmadi A2, Silberg DG1, Erder M1 
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OBJECTIVES: The purpose of this research was to develop an electronic daily sign 
and symptom diary, the Daily Ulcerative Colitis Scale (DUCS), including a patient 
reported outcomes (PRO) version for children 8-17 years and an observer 
reported outcomes (ObsRO) version for caregivers of children aged 5-10 years. 
METHODS: Open-ended one-on-one concept elicitation interviews were 
conducted with children aged 8-17 years with a documented history of mild to 
moderate ulcerative colitis confirmed by endoscopy, recruited from three clinical 
centers. The interviews focused on signs or symptoms associated with UC. In 
addition, five pediatric gastroenterologists and three nurses were interviewed 
about the pediatric UC signs/symptoms, and parent blogs on an active UC 
website were reviewed; the blogs included discussions on 26 children with UC. 
Interview transcripts were developed, and a thematic analysis was conducted in 
which each new concept identified was coded using MaxQDA. RESULTS: The 
concept elicitation interviews included 22 children in remission (six aged 8-12; 16 
aged 13-17) and 10 children with active disease (four aged 8-12; six aged 13-17). 
Information saturation (i.e., no new information reported in last patient 
interview) was achieved. A core set of seven signs/symptoms in pediatric UC 
emerged: abdominal pain, blood in stool, frequent stools, diarrhea, stool urgency, 
nocturnal stools, and tiredness. No substantial differences were observed across 
different ages, and descriptions were largely consistent across patients. Even 
when in remission, children reported occasional symptoms. The HCP interviews 
and blog data substantiated the interview findings; the HCPs confirmed that 
signs/symptoms of UC do not vary by age. CONCLUSIONS: Children with UC 
were able to report their signs/symptoms associated with UC, and these data 
informed the development of two measures with phrasing that should resonate 
with the pediatric and caregiver populations. These will be tested in cognitive 
debriefing interviews.  
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OBJECTIVES: To analysis of the pattern of the consumption of histamine H2-
receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) (ATC subgroup 
A02B) in Serbia in correlation with Scandinavian countries (Denmark, Norway, 
Sweden and Finland). METHODS: The data on consumption of medicines during 
the four-year period (2007-2010) have been provided from the databases of the 
national regulatory agencies. The results were expressed as the number of 
defined daily doses per 1000 inhabitants per day (DID). A qualitative analysis was 
carried out according to the drug utilization 90% (DU90%) approach. RESULTS: 
During the period 2007-2010, the overall consumption of A02B subgroup 
medicines in Serbia decreased by 7.8%, opposite to Scandinavian countries 
where the consumption continuously increased in all countries, up to 56% in 
Denmark. In 2010, H2RAs accounted for 71.78% (16.46DID) of medicines used 
within A02B subgroup in Serbia, while in Scandinavian countries the share of 
H2RAs was in the range of 1.08 DID in Sweden up to 5.75 DID in Norway. Despite 
the increase by 34.3%, consumption of PPIs in 2010 in Serbia (6.45 DID) was up to 
7.6 times lower than in the Scandinavian countries (49.1 DID in Denmark). The 
bulk of prescription (DU90%) in 2010 was made up of 3 (out of 7) medicines in 
Serbia, 2, 4 and 5 (out of 14) medicines in Sweden, Denmark and Finland 
respectively, and 5 (out of 10) medicines in Norway. Most frequently used 
medicine in Serbia was ranitidine (55.9%), in Sweden and Denmark omeprazole 
(80.3% and 30.3% respectively), in Norway esomeprazole (34.1%) and in Finland 
pantoprazole (28.5%). CONCLUSIONS: The overall utilization of medicines from 
A02B subgroup was notably lower in Serbia than in Scandinavian countries. 
Besides the quantity, the pattern of use showed significant differences 
suggesting that implementation of guidelines in Serbia is needed in order to 
achieve harmonization in prescribing practice.  
 
PGI27  
EVALUATION OF OUTPATIENT HEALTH CARE AND MEDICATION UTILIZATION 
IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS/HEPATITIS C VIRUS 
(HIV/HCV), HIV, OR HCV INFECTION IN THE UNITED STATES  
Johnson T, Toliver J, Oramasionwu CU 
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OBJECTIVES: Few studies have explored how utilization of outpatient services 
differ for HIV/HCV coinfected patients compared to HIV or HCV monoinfected 
patients. The objectives of this study were to compare annual outpatient clinic 
visit rates between coinfected and monoinfected patients and to compare 
utilization of HIV and HCV therapies between coinfected and monoinfected 
patients. METHODS: Data were retrieved from the 2005-2010 National Hospital 
Ambulatory Medical Care Surveys. Clinic visits with a primary or secondary ICD-
9-CM diagnosis code for HIV or HCV were included. Coinfection included visits 
with both HIV and HCV codes. Monoinfection included visits with only HIV or 
HCV codes. Patients <15 years of age at time of visit were excluded. Demographic 
characteristics and select comorbidities were compared by infection status using 
chi-square and ANOVA tests. Visit rates were computed using survey weights. 
RESULTS: Approximately 11,352,000 visits met study criteria for patients with 
HIV/HCV (8%), HIV (70%), or HCV (22%). The HCV cohort was older and had the 
highest proportion of females and whites as compared to HIV/HCV and HIV 
cohorts. The following comorbidities varied significantly across the three cohorts 
(HIV/HCV, HIV, HCV): current tobacco use (40%, 27%, 30%), depression (32%, 23%, 
24%), diabetes (9%, 10%, 17%), and chronic renal failure (<1%, 3%, 5%), (p<0.001 for 
all variables). HIV/HCV visit rates were lower than both HIV and HCV visits rates 
and varied little across all study years. In contrast, there was a decrease in 
annual HIV visit rates and an increase in annual HCV visit rates. HIV therapy 
utilization increased for both HIV/HCV and HIV cohorts; the increase was more 
pronounced in the HIV/HCV cohort. HCV therapy utilization remained low for 
both HIV/HCV and HCV cohorts for all years. CONCLUSIONS: Low utilization of 
HCV therapy for HIV/HCV patients and HCV patients warrants further 
investigation.  
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TREATMENT PATTERNS OF ADALIMUMAB AND INFLIXIMAB IN THE 
TREATMENT OF CROHN'S DISEASE OVER A THREE-YEAR PERIOD: A CANADIAN 
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OBJECTIVES: A previous study indicated that after one year, the proportion of 
patients with a dose augmentation was higher with infliximab than with 
adalimumab. The objective of this study was to analyze, in a real world setting, 
trends in dose changes over a three-year period. METHODS: A retrospective 
cohort study was conducted using data from the Regie de l'assurance maladie du 
Quebec (RAMQ) for a randomly selected group of patients with a CD diagnosis, 
who had initiated (6month washout period) adalimumab or infliximab between 
February 2008 and March 2011. For adalimumab, dose increase was considered 
when the dose received exceeded 40mg every other week over at least an 8-week 
period. For infliximab, dose increase was considered either when the dose was 
increased or interval between doses was reduced for two periods of 8 weeks after 
the third injection. Statistical analyses were conducted using chi square test. 
RESULTS: The cohort included 1,517 patients (mean age: 33.9 years, 55.4% 
females). During the study period, 1,004 patients initiated infliximab (28 
previously used adalimumab) and 513 patients initiated adalimumab (195 
previously used infliximab). After 36 months, 28.2%(275/976) of patients with 
infliximab and 23.0%(73/318) of patients with adalimumab experienced a dose 
increase (p<0.05). For the non-naive patient subgroups, dose escalation occurred 
for 42.9%(12/28) with infliximab and for 27.2%(53/195) with adalimumab (p<0.05). 
Average annual cost of adalimumab was CDN$26,957 and CDN$18,577 for 
